Razupenem
![]() | |
Systematic (IUPAC) name | |
---|---|
(4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-3-((4-((S)-5-methyl-2,5-dihydro-1H-pyrrol-3-yl)thiazol-2-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | |
Clinical data | |
Trade names | PTZ-601 |
| |
IV | |
Identifiers | |
![]() | |
ChemSpider |
9168406 ![]() |
Chemical data | |
Formula | C18H21N3O4S2 |
407.51 g/mol | |
SMILES
| |
|
Razupenem (PTZ-601) is a broad spectrum injectable antibiotic, from the carbapenem subgroup of beta-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics.[1] Razupenem performed well against a variety of bacterial strains,[2] but further development is in doubt due to a high rate of side effects in Phase II clinical trials.
References
- ↑ Livermore, D. M.; Mushtaq, S.; Warner, M. (2009). "Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms". Journal of Antimicrobial Chemotherapy 64 (2): 330–335. doi:10.1093/jac/dkp187. PMID 19497942.
- ↑ Tran, C. M.; Tanaka, K.; Yamagishi, Y.; Goto, T.; Mikamo, H.; Watanabe, K. (2011). "In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria". Antimicrobial Agents and Chemotherapy 55 (5): 2398–2402. doi:10.1128/AAC.01038-10. PMC 3088197. PMID 21343447.
|